Medical management of gastric cancer: A 2014 update

Table 1 Major phase III trials for gastric cancer in the localized setting

Ref.	n	Treatment arms	HR for overall survival or death (P value)	Survival comparison
Macdonald et al[23]	556	Surgery and chemoradiotherapy1vs surgery	1.35 (0.005)	Overall survival: 36 mo vs 27 mo
Cunningham et al[24]	503	ECF, surgery, ECF vs surgery	0.75 (0.009)	5-yr overall survival: 36.3% vs 23%
Fuchs et al[62]	546	5-FU, chemoradiotherapy, 5-FU vs ECF, chemoradiotherapy, ECF	1.03 (0.800)	Overall survival: 37 mo vs 38 mo
Lee et al[31]	458	Surgery and XP vs surgery, XP, XRT, XP	HR for DFS 0.6865 (0.0471)	3-yr DFS: 74.2% vs 78.2%
Sakuramoto et al[25]	1059	Surgery vs surgery and S-1	0.68 (0.003) 5 yr data in JCO 0.669	3-yr overall survival: 70.1% vs 80.1%
				3-yr RFS: 72.2% vs 59.6%
Bang et al[26]	1035	XELOX and surgery vs surgery	0.56 (< 0.0001)	3-yr DFS: 74% vs 59%
Ychou et al[28]	224	Perioperative chemotherapy vs surgery	0.69 (0.02)	5-yr overall survival: 38% vs 24%
Tsuburaya et al[63]	1495	Surgery and UFT vs surgery and S-1 vs surgery, paclitaxel and UFT vs surgery, paclitaxel and S-1	NR	NR
ARTIST II[64]	1000	Surgery and S1Ox vs surgery, S1Ox, XRT and S1Ox	NR	NR
Okines et al[65]	1100	ECX and bevacizumab vs ECX	NR	NR
Leong et al[33]	752	Preoperative chemotherapy vs preoperative chemoradiotherapy	NR	NR

¹Forty-five Gy radiotherapy plus 5-FU. Ongoing trial; Hazard ratio reduced to 0.8 on follow-up analysis. 5-FU: 5-Fluorouracil; ASC: Active symptom control; BSC: Best supportive care; CapeOx: Capecitabine and oxaliplatin; CF: Cisplatin and 5-FU; CX: Cisplatin and capecitabine; DFS: Diseas-free survival; ECF: Epirubicin, cisplatin and 5-FU; ECX: Epirubicin, cisplatin and capecitabine; EOC: Epirubicin, oxaliplatin and capecitabine; HR: Hazard ratio; mEOC–P: EOC plus panitumumab; PFS: Progression-free survival; RFS: Relapse-free survival; UFT: Tegafur and uracil; XELOX: Capecitabine and oxaliplatin; XP: Capecitabine and cisplatin; S1Ox: S1 and oxaliplatin; XRT: Chemoradiation.